ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
13.06
+2.11 (19.27%)
At close: Jan 9, 2026, 4:00 PM EST
13.00
-0.06 (-0.47%)
After-hours: Jan 9, 2026, 7:59 PM EST
ARS Pharmaceuticals Employees
As of December 31, 2024, ARS Pharmaceuticals had 160 total employees, including 155 full-time and 5 part-time employees. The number of employees increased by 134 or 515.38% compared to the previous year.
Employees
160
Change (1Y)
134
Growth (1Y)
515.38%
Revenue / Employee
$892,325
Profits / Employee
-$500,250
Market Cap
1.29B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 160 | 134 | 515.38% |
| Dec 31, 2023 | 26 | 6 | 30.00% |
| Dec 31, 2022 | 20 | 11 | 122.22% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SPRY News
- 1 day ago - Bad News For Competitor Turns Into Big Win For ARS Pharma Stock - Benzinga
- 12 days ago - neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) - GlobeNewsWire
- 6 weeks ago - ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating - Seeking Alpha
- 2 months ago - ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray) - GlobeNewsWire
- 2 months ago - ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray) - GlobeNewsWire
- 2 months ago - UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - GlobeNewsWire